The new cloud-based data analytics platform is designed to reduce the complexity of deploying an antibiotic for complicated abdominal infections.
Shyft Analytics — recently acquired by Medidata Solutions — has created an intelligent platform for life sciences. The company announced its selection by Tetraphase Pharmaceuticals to assist in the upcoming commercial launch of an antibiotic that addresses drug-resistant bugs in complicated abdominal infections. The drug, Eravacycline, will launch once it receives regulatory approval.
Shyft’s cloud-based, scalable platform will give Tetraphase the tools it needs to gain:
- Commercial insights
- Market intelligence
- Deep analytics
Tetraphase will use Shyft’s Life Sciences platform to integrate multiple data sources and create a comprehensive view of both clinical and commercial information. The intelligent analytics platform will provide Tetraphase with the insights and analytics necessary to support a successful launch and insight into patient and payer needs.
See also: 3 ways AI can remedy the bloated healthcare system
“Shyft’s right-sized and scalable approach, combined with their deep expertise in helping specialty pharma brands successfully and quickly derive insights, will help us better address physician and patient needs, meet commercial milestones, and ensure we can scale to surpass our launch goals,” says Tetraphase COO Larry Edwards.
“Addressing the increase in antibiotic resistance relies on effective novel therapies like Tetraphase’s Eravacycline,” says Zack King, EVP Medidata, President of Shyft. “A product’s success in this therapeutic area requires a thorough understanding of the market, patients, and unique differentiators. We’re honored to partner with the Tetraphase team on an innovative approach to data analytics to ensure that new and life-changing therapies have the opportunity to thrive in an ever-changing, complex market. This is core to Shyft’s mission.”
